JOHNSON & JOHNSON — Director's Dealing 2023

Nov 2, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2023-10-23

Reporting Person: Schmid Timothy (EVP, WW Chair, MedTech)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8979.0000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (Right to Buy)	$101.8700	2026-02-08	Common Stock (15571.0000)		Direct
Employee Stock Options (Right to Buy)	$115.6700	2027-02-13	Common Stock (13625.0000)		Direct
Employee Stock Options (Right to Buy)	$129.5100	2028-02-11	Common Stock (8998.0000)		Direct
Employee Stock Options (Right to Buy)	$131.9400	2029-02-11	Common Stock (11070.0000)		Direct
Employee Stock Options (Right to Buy)	$151.4100	2030-02-10	Common Stock (22527.0000)		Direct
Employee Stock Options (Right to Buy)	$162.7500	2033-02-13	Common Stock (12388.0000)		Direct
Employee Stock Options (Right to Buy)	$164.6200	2031-02-08	Common Stock (21574.0000)		Direct
Employee Stock Options (Right to Buy)	$165.8900	2032-02-14	Common Stock (17431.0000)		Direct
Restricted Share Units	$		Common Stock (1497.0000)		Direct
Restricted Share Units	$	2024-02-08	Common Stock (1964.0000)		Direct
Restricted Share Units	$	2025-02-14	Common Stock (1765.0000)		Direct

Footnotes

F1: The Stock Option Award was granted on February 13, 2023 and vests in three equal annual installments beginning on the first anniversary of the grant date.

F2: The Restricted Share Units were granted on February 13, 2023 and vest in three annual equal installments beginning on the first anniversary of the grant date.

F3: Each Restricted Share Unit represents a contingent right to acquire one share of Company Common Stock.